Direct CNS Leucine Delivery for Lysosomal Disease Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for neurodegenerative diseases and lysosomal storage disorders (LSDs) are limited, with few curative treatments, and there is a need for improved therapies to prevent or reduce symptoms such as impaired mobility and cognitive decline, which are often associated with ageing.
Innovation Solution
Leucine or its pharmaceutically acceptable salts are administered directly to subjects in need, for methods that include treating, delaying onset, reversing progression, or improving symptoms of neurodegenerative diseases and LSDs, through direct delivery to the central nervous system via various routes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If current therapeutic approaches are used for neurodegenerative diseases and LSDs, then treatment options are limited, but curative treatments are few or non-existent
Solution Approach 1:
The patent changes the chemical parameter by using acetyl-leucine (an acetylated derivative) instead of conventional leucine supplements. This chemical modification enables the compound to cross the blood-brain barrier and directly target lysosomal dysfunction in the central nervous system, transforming a non-specific supplement into a targeted therapeutic agent that addresses both lysosomal storage and neurodegenerative pathways
Solution Approach 2:
Acetyl-leucine acts as an intermediary substance that bridges the gap between peripheral lysosomal therapy and central nervous system treatment. The acetyl group serves as a transient carrier that facilitates blood-brain barrier penetration, delivers leucine to lysosomes, and is subsequently removed by lysosomal acetyl-CoA, releasing active leucine where needed
2Ease of operation
If lysosomal storage disorders are treated with existing therapies, then quality of life may be improved, but disease progression is not halted
Solution Approach 1:
The patent implements preliminary protective action by administering acetyl-leucine before severe neurodegenerative damage occurs. The compound proactively reduces lysosomal volume and prevents storage material accumulation, thereby delaying disease onset and progression while maintaining quality of life, rather than merely responding to established symptoms
3Ease of operation
If age-related cognitive decline and mobility problems are addressed, then symptoms may be managed, but underlying neurodegenerative processes continue
Solution Approach 1:
Acetyl-leucine serves multiple functions simultaneously: it manages symptoms by improving cognitive function and mobility, while also addressing the underlying cause by reducing lysosomal volume and inhibiting neurodegenerative processes. This multi-functionality resolves the contradiction between symptomatic relief and disease modification
Data Source
AI summary
The present disclosure provides for treating neurodegenerative diseases and lysosomal storage disorders comprising administering leucine, or a pharmaceutically acceptable salt thereof for direct delivery in a subject in need thereof. The disclosure further provides for leucine, or a pharmaceutically acceptable salt thereof for direct delivery in a subject in need thereof, for example, in an elderly subject, to improve cognitive function, mobility, or cognitive function and mobility.